StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly other Cardiometabolic Health medicines — U.S. revenue ($M) ($M)

Form 10-Q / 10-K Note 2 Disaggregated Revenue

QuarterlyAnnual
Latest, Q2 2026
554
Period ended Jun 30, 2026
Change on a year earlier
-0.4%
556 in Q2 2025
History
13 quarters
Since Q2 2023
Sources
8
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Cardiometabolic Health medicines — U.S. revenue ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026554-0.4%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026446-16.6%Form 10-Q (filed 2026-04-30) ↗
Q4 2025Dec 31, 2025525-27.5%Form 10-K (filed 2026-02-12) ↗
Q3 2025Sep 30, 2025618+2.4%Form 10-Q (filed 2025-10-30) ↗
Q2 2025Jun 30, 2025556-26.2%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 2025535-11.1%Form 10-Q (filed 2026-04-30) ↗
Q4 2024Dec 31, 2024723-72.3%Form 10-K (filed 2026-02-12) ↗
Q3 2024Sep 30, 2024603+1,034.0%Form 10-Q (filed 2025-10-30) ↗
Q2 2024Jun 30, 2024754+1,574.7%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 2024602–Form 10-Q (filed 2025-05-01) ↗
Q4 2023Dec 31, 20232,607–Form 10-K (filed 2026-02-12) ↗
Q3 2023Sep 30, 202353.2–Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 202345–Form 10-Q (filed 2024-08-08) ↗

Breakdown

What makes up other cardiometabolic health medicines — u.s. revenue ($m)

Cite this data

StockData. (2026). Eli Lilly Other Cardiometabolic Health medicines — U.S. revenue ($M) ($M), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_other_cm_us

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.